Global Antibody Hit Generation and Screening Market: Analysis and Forecast, 2023-2032
The Global Antibody Hit Generation and Screening Market report offers a detailed and comprehensive analysis of the industry, providing valuable insights into market trends, growth drivers, challenges, and future opportunities. The report covers key segments, competitive landscape, and emerging technologies, offering stakeholders a holistic view of the global market.
The study identifies and analyzes the primary drivers influencing market growth. Factors such as the increasing prevalence of chronic diseases, advancements in antibody engineering, and rising investments in research and development are explored. Additionally, the growing demand for personalized medicine and the expanding biopharmaceutical industry contribute to the positive trajectory of the market.
Market Segmentation:
Segmentation 1: by Application
Cancer
Autoimmune diseases
Infectious diseases
Segmentation 2: by Technologies
Hit Generation
Phage display
Yeast display
Ribosome display
B-cell hybridoma technology
Computational tools
Screening
Segmentation 3: by Antibody Type
Humanized Antibody
Human Antibody
Chimeric Antibody
Murine Antibody
Segmentation 4: by Region
North America
Europe
Asia-Pacific
Latin America
Rest-of-the-World
Some prominent players established in this market are:
Creative Biolabs
F. Hoffmann-La Roche Ltd.
WuXi AppTec
Icos Therapeutics
Key Questions Answered:
What are the major market drivers, challenges and opportunities in the global antibody hit generation and screening market?
How the antibody hit generation and screening market evolves and what did is its scope in the future?
How will each segment of the global antibody hit generation and screening market grow during the forecast period?
How will the industry evolve during the forecast period?
What are the key developmental strategies implemented by the key players to stand out in this market?
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- Executive Summary
- Scope of the Study
- Research Methodology
- 1. Market
- 1.1 Global Market Outlook
- 1.2 Product Definition
- 1.3 Inclusion and Exclusion Criteria
- 1.4 Key Findings
- 1.5 Assumptions and Limitations
- 1.6 Global Market Scenario
- 1.6.1 Realistic Scenario
- 1.6.2 Optimistic Scenario
- 1.6.3 Pessimistic Scenario
- 1.7 Industry Outlook
- 1.8 Key Trends
- 1.9 Patent Analysis
- 1.9.1 Awaited Technological Developments
- 1.9.2 Patent Filing Trend (by Country/Cluster)
- 1.9.3 Patent Filing Trend (by Year)
- 1.10 Product Benchmarking
- 1.11 Impact of COVID-19 on Global Antibody Hit Generation and Screening Market
- 1.12 Impact on Market Size
- 1.12.1 Pre-COVID-19 Phase
- 1.12.2 During-COVID-19 Phase
- 1.12.3 Post-COVID-19 Phase
- 1.13 Market Entry Barriers and Opportunities
- 1.14 Business Dynamics
- 1.15 Impact Analysis
- 1.15.1 Business Drivers
- 1.15.2 Business Restraints
- 1.15.3 Business Opportunities
- 2. Global Antibody Hit Generation and Screening Market (by Technologies)
- 2.1 Opportunity Assessment
- 2.2 Growth Share Matrix
- 2.2.1 Hit Generation
- 2.2.2 Phage display
- 2.2.3 Yeast display
- 2.2.4 Ribosome display
- 2.2.5 B-cell hybridoma technology
- 2.2.6 Computational tools
- 2.2.7 Screening
- 3. Global Antibody Hit Generation and Screening Market (by Antibody Type)
- 3.1 Opportunity Assessment
- 3.2 Growth Share Matrix
- 3.2.1 Humanized Antibody
- 3.2.2 Human Antibody
- 3.2.3 Chimeric Antibody
- 3.2.4 Murine Antibody
- 4. Global Antibody Hit Generation and Screening Market (by Applications)
- 4.1 Opportunity Assessment
- 4.2 Growth Share Matrix
- 4.2.1 Cancer
- 4.2.2 Autoimmune diseases
- 4.2.3 Infectious diseases
- 5. Region
- 5.1 North America Antibody Hit Generation and Screening Market
- 5.2 Key Findings and Opportunity Assessment
- 5.3 Regulatory Framework
- 5.4 Market Dynamics
- 5.4.1 Impact Analysis
- 5.5 Sizing and Forecast Analysis
- 5.5.1 North America Antibody Hit Generation and Screening Market (by Technologies)
- 5.5.2 North America Antibody Hit Generation and Screening Market (by Country)
- 5.5.2.1.1 U.S.
- 5.5.2.1.2 Canada
- 5.6 Europe Antibody Hit Generation and Screening Market
- 5.7 Key Findings and Opportunity Assessment
- 5.8 Regulatory Framework
- 5.9 Market Dynamics
- 5.9.1 Impact Analysis
- 5.10 Sizing and Forecast Analysis
- 5.10.1 Europe Antibody Hit Generation and Screening Market (by Technologies)
- 5.10.2 Europe Antibody Hit Generation and Screening Market (by Country)
- 5.10.2.1.1 Germany
- 5.10.2.1.2 France
- 5.10.2.1.3 U.K.
- 5.10.2.1.4 Italy
- 5.10.2.1.5 Spain
- 5.10.2.1.6 Rest-of-Europe
- 5.11 Asia-Pacific Antibody Hit Generation and Screening Market
- 5.12 Key Findings and Opportunity Assessment
- 5.13 Regulatory Framework
- 5.14 Market Dynamics
- 5.14.1 Impact Analysis
- 5.15 Sizing and Forecast Analysis
- 5.15.1 Asia-Pacific Antibody Hit Generation and Screening Market (by Technologies)
- 5.15.2 Asia-Pacific Antibody Hit Generation and Screening Market (by Country)
- 5.15.2.1.1 Japan
- 5.15.2.1.2 China
- 5.15.2.1.3 Australia
- 5.15.2.1.4 India
- 5.15.2.1.5 South Korea
- 5.15.2.1.6 Rest-of-Asia-Pacific
- 5.16 Latin America Antibody Hit Generation and Screening Market
- 5.17 Key Findings and Opportunity Assessment
- 5.18 Regulatory Framework
- 5.19 Market Dynamics
- 5.19.1 Impact Analysis
- 5.20 Sizing and Forecast Analysis
- 5.20.1 Latin America Antibody Hit Generation and Screening Market (by Technologies)
- 5.20.2 Latin America Antibody Hit Generation and Screening Market (by Country)
- 5.20.2.1.1 Brazil
- 5.20.2.1.2 Mexico
- 5.20.2.1.3 Rest-of-Latin America
- 5.21 Rest-of-the-World Antibody Hit Generation and Screening Market
- 5.22 Key Findings and Opportunity Assessment
- 5.23 Regulatory Framework
- 5.24 Market Dynamics
- 5.24.1 Impact Analysis
- 5.25 Sizing and Forecast Analysis
- 5.25.1 Rest-of-the-World Antibody Hit Generation and Screening Market (by Technologies)
- 6. Markets
- 6.1 Competitive Benchmarking and Company Profiles
- 6.2 Competitive Landscape
- 6.2.1 Key Strategies and Developments
- 6.2.1.1.1 Partnerships, Alliances, and Business Expansion
- 6.2.1.1.2 Funding Activities
- 6.2.1.1.3 New Offerings
- 6.2.1.1.4 Mergers and Acquisitions
- 6.2.1.1.5 Regulatory and Legal Activities
- 6.3 Company Profiles
- 6.3.1 F. Hoffmann-La Roche Ltd.
- 6.3.2 Company Overview
- 6.3.3 Product Portfolio
- 6.3.4 Financials
- 6.3.5 Recent Developments
- 6.3.6 Analyst Perspective
- 6.3.7 AbbVie
- 6.3.8 Pfizer
- 6.3.9 AstraZeneca
- 6.3.10 Novartis
- 6.3.11 Eli Lilly
- 6.3.12 WuXi AppTec
- 6.3.13 Charles River Laboratories
- 6.3.14 Syngenta
- 6.3.15 BioLegend
- 6.3.16 Creative Biolabs
- 6.3.17 Eurofins CDMO
- 6.3.18 AbCellera
- 6.3.19 MorphoSys
- 6.3.20 Evelo Biosciences
- 6.3.21 Icos Therapeutics
- 6.3.22 Argenx
- 6.3.23 Kymab
- 6.3.24 Alnylam Pharmaceuticals
- 6.3.25 SAb Biotherapeutics
- 6.3.26 Other Companies
- ** Financials are provided for the public companies only
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook